Linked Life Data

20425320

Source:http://linkedlifedata.com/resource/pubmed/id/20425320

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-4-28
pubmed:abstractText
Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination regimens. Combinations of monoclonal antibodies with chemotherapy agents (chemoimmunotherapy) have proved especially powerful, almost doubling clinical complete response rates compared with chemotherapy alone. In addition to an increase in the number of responders, eradication of residual disease and achievement of molecular responses have become possible, leading to novel treatment concepts including consolidation and maintenance. New therapeutic agents and vaccines are in development and are being evaluated in clinical trials. Cytogenetic-molecular characterization has begun to be tailored into treatment considerations and it is hoped that the combination of molecular biology with effective therapies will lead to risk-adapted strategies and improved survival.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1558-822X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
251-7
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
New aspects of the treatment of chronic lymphocytic leukemia.
pubmed:affiliation
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. sfaderl@mdanderson.org
pubmed:publicationType
Journal Article, Review